You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

 

272 Results
Guidelines and Advice
Status: Current
ID: PET 2019-2
Version: N/A
Dec 1969
Document
Sep 2020
Cancer facts
Oct 2020
Trouvez des liens vers des pages d’information sur les soins de cancérologie offerts en Ontario pendant la pandémie de COVID-19.
Cancer facts
Jan 2016
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal, 
Small bowel and appendix
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    encorafenib - In combination with cetuximab or panitumumab in previously treated BRAF V600E-mutated metastatic colorectal cancer, according to clinical criteria
New Drug Funding Program
    Cetuximab - In Combination with Encorafenib for Previously Treated Metastatic Colorectal Cancer
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
encorafenib,
cetuximab
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Guidelines and Advice
Status: Current
ID: PET 2020-1
Version: N/A
Nov 2020
Cancer facts
Nov 2020
Guidelines and Advice
Status: Current
Version: 1.0
Dec 1969
Cancer facts
Jan 2021
Drug
Other Name(s): Idhifa®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Jul 2023

Pages